Spectrum Pharm. Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate

[at noodls] – Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia In U.S.-based Phase 1 trial, SPI-2012 demonstrated increase … more

View todays social media effects on SPPI

View the latest stocks trending across Twitter. Click to view dashboard

See who Spectrum is hiring next, click here to view